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Abstract 
Primary sclerosing cholangitis (PSC) frequently progresses to end-stage liver disease and 
cirrhosis, requiring liver transplantation. Approximately 70% of patients with PSC have 
concomitant inflammatory bowel disease (IBD) during their clinical course. After liver 
transplantation for PSC, corticosteroids and other high-intensity immunosuppressants are 
initiated to keep IBD in remission. Patients with IBD that is refractory to these agents may need 
to be managed with biologic therapies. Biologic agents, however, may further increase the risks 
for malignancy and infection due their immunosuppressive effects. Thus, to gain a better 
understanding of the risks and benefits of these agents in this high-risk patient population, we 
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performed a literature search of the PubMed database (2002–2017) to identify studies 
assessing the efficacy and safety of various biologic agents for the management of IBD in liver 
transplant recipients. No randomized controlled studies or retrospective comparative studies 
were identified; however, 15 case reports and case series were identified that met our inclusion 
criteria. From these case reports, we identified 67 patients who developed de novo or recurrent 
IBD after liver transplantation and received anti–tumor necrosis factor-α or anti-integrin 
therapy. Of the 13 published cases reporting clinical response or remission of IBD activity in 
liver transplant recipients (59 patients), clinical response or remission of IBD was reported in 38 
(64.4%) of those patients. Adverse complications reported included cholangitis, oral candidiasis, 
Clostridium difficile colitis, bacterial pneumonia, cryptosporidiosis, Epstein-Barr virus–positive 
post-transplantation lymphoproliferative disease, and hepatotoxicity. Given the limited 
literature (case reports and case series) highlighted in this review, biologic agents such as tumor 
necrosis factor-α inhibitors and integrin inhibitors commonly used for moderate to severe IBD 
may be appropriate after liver transplantation; however, consideration of risk versus benefit 
should always occur in a patient-specific manner. 
 
 
 
Introduction 
Primary sclerosing cholangitis (PSC) is a rare occurrence among the general population, with an 
incidence rate of 0.77 per 100,000 person-years, and it most commonly occurs in middle-aged 
men [1, 2]. This chronic cholestatic disease of the liver and bile ducts, characterized by fibrosis 
of the intrahepatic and extrahepatic bile ducts, frequently progresses to end-stage liver disease 
and cirrhosis, requiring liver transplantation.  
     Although the pathogenesis of PSC is not completely understood, it is theorized that PSC is 
the result of an autoimmune process given its tight association with inflammatory bowel 
disease (IBD). Approximately 70% of patients with PSC have concomitant IBD during their 
clinical course, with ulcerative colitis (UC) predominating [2]. The traditional view of the 
pathogenesis of IBD is that intestinal inflammation is mediated by infiltration of leukocytes in 
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intestinal mucosa and derangements in intestinal barrier function. During IBD, intestinal 
inflammation is mediated by cells of the acquired immune system, with overly aggressive 
activity of effector lymphocytes and proinflammatory cytokines (tumor necrosis factor [TNF]) 
contributing to the symptoms seen in Crohn’s disease and UC [3]. After liver transplantation for 
PSC, corticosteroids are initiated, as well as other high-intensity immunosuppressants, that may 
keep IBD in remission. However, despite immunosuppression, there is evidence demonstrating 
both recurrence of IBD or de novo IBD in liver transplant recipients [4]. Significant risk factors 
for IBD recurrence and de novo IBD after liver transplantation include IBD prior to orthotopic 
liver transplantation (OLT), use of tacrolimus, cytomegalovirus mismatch status, IBD symptoms 
at time of OLT, and short time interval between diagnosis of IBD and OLT [4].  
     Patients with corticosteroid- or immunomodulatory therapy–refractory IBD may need to be 
managed with biologic therapies, including antibody products acting against TNF-α and integrin. 
In a patient population already at high risk for malignancy and infection, biologic agents may 
further increase these risks given their immunosuppressive effects. Therefore, it becomes 
important to assess the safety and efficacy of these agents in patients with IBD after liver 
transplantation. Unfortunately, to our knowledge, no randomized controlled studies or 
retrospective comparative studies were identified to assess the safety and efficacy of these 
agents for IBD after liver transplantation. However, several case reports and case series were 
identified to help explore the use of these agents in this patient population, which is the focus 
of this review.  
 
Background 
Association Between PSC and IBD 
Several theories exist to describe the association between PSC and IBD, linking PSC to an 
autoimmune pathophysiology. A study by Henriksen was conducted to investigate whether 
clonally related T-cells were present in paired tumor-adjacent normal gut and liver tissue 
sampled from patients with colon cancer[5].  The study was able to demonstrate that memory 
T-cells of common clonal origin were detected in paired gut and liver samples in patients with 
PSC and IBD concomitantly (PSC-IBD). These T-cells react to similar triggers and are 
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proportionally high in patients with PSC-IBD. To further link PSC to an immunogenic 
mechanism, immunogenicity studies have identified a number of key human leukocyte antigen 
(HLA) haplotypes associated with PSC. Specifically, the haplotype HLA-B8/DR3 has been 
implicated in patients with PSC-IBD, and is infrequent in PSC alone [6].  
     The clinical presentation and prognosis of PSC and IBD are also similar owing to the 
association between the two. Patients with PSC-IBD have an increased incidence of pancolitis, 
rectal-sparing disease, backwash ileitis, and milder symptoms [7]. Moreover, both PSC and IBD 
are associated with colorectal cancer, with an increased risk in patients with PSC-IBD likely due 
to an accumulation of secondary bile acids causing DNA damage and promoting cell mutation 
[8]. Given that patients with PSC-IBD have much milder symptoms of IBD, it can often go 
unrecognized and untreated, which may also increase the risk of colorectal cancer, as extent 
and duration of colitis are known risk factors for malignancy [8]. IBD after liver transplantation 
has severe consequences, including increased risk for graft rejection and need for 
retransplantation [9]. Therefore, it is important to recognize those patients at risk for de novo 
or recurrent IBD after liver transplantation and optimize management to control IBD activity.  
 
Management of PSC 
     There are a limited number of treatment options for PSC that may be used prior to liver 
transplantation such as ursodeoxycholic acid, endoscopic therapy, and biliary surgery. These 
treatment modalities have not been shown to slow down the progression of PSC but certainly 
have been shown to have other benefits. Ursodeoxycholic acid has been the only 
pharmacologic therapy to demonstrate a positive effect for PSC by improving biochemistry, 
histology, and symptoms, as well as decreasing the incidence of colorectal cancer and 
cholangiocarcinoma [10]. However, the only treatment option for PSC leading to end-stage liver 
disease is liver transplantation [10]. Patients who undergo liver transplantation for PSC are at 
an increased risk for recurrence of IBD or the development of de novo IBD due to inappropriate 
and ongoing activation of the mucosal immune system. Furthermore, after liver 
transplantation, patients receive immunosuppressive medications that may lead to infections 
Au
th
or
 M
an
us
cr
ip
t
  
This article is protected by copyright. All rights reserved 
6 
affecting the microbial flora, which, in turn, may result in a decrease in intestinal barrier 
function.  
 
Management of IBD after Liver Transplantation 
     Management of IBD after liver transplantation has not been well established, with 
recommendations to use cyclosporine instead of tacrolimus for maintenance 
immunosuppression, avoid mycophenolate mofetil to minimize the risk of enterocolitis, and use 
biologic agents for refractory cases of IBD [11]. However, the evidence supporting these 
recommendations is based on small retrospective cohort studies with conflicting data. In 
patients with refractory or moderate to severe IBD, biologic agents are often required to 
minimize and maintain IBD activity. Currently, six biologic agents have been approved by the 
United States Food and Drug Administration (FDA) for IBD, which include inhibitors of TNF-α 
and integrin.  
 
Tumor Necrosis Factor-α–Based Therapies 
TNF-α, a proinflammatory cytokine, is produced by activated macrophages and T-lymphocytes, 
and proceeds to recruit neutrophils to local sites of inflammation. As demonstrated in 
randomized controlled trials, neutralizing TNF-α with biologic agents allows for disease 
remission in patients with IBD [12-15]. Therefore, these monoclonal antibodies have become 
the pharmacologic agents of choice for the management of moderate to severe IBD.      
     Four FDA-approved TNF-α inhibitors are currently available for the treatment of IBD: 
infliximab, adalimumab, certolizumab, and golimumab. These various TNF-α inhibitors slightly 
differ in the source (e.g., mouse, human) used to develop the antibody; however, this does not 
alter the efficacy and safety profiles among the products. Several studies report safety concerns 
with TNF-α inhibitors including hepatotoxicity, infectious risks, and malignancy [12-15].  
 
Integrin-Based Therapies 
Integrins are involved in multiple pathways that lead to the development of IBD and therefore 
have become a newly targeted area of interest for drug development. Integrins are 
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heterodimers composed of α and β subunits that undergo conformational changes in the 
response to signaling events inside the cell and function as adhesion receptors that connect 
cells to ligands in the extracellular matrix to other cells [16]. Lymphocytes play a crucial role in 
the pathogenesis of IBD, and their journey from the vascular space into the gut tissue is 
regulated by adhesion molecules and requires multiple steps. The first step in the journey of a 
leukocyte from circulation into tissue is an interaction with postcapillary vessel endothelium. 
This process is facilitated by an adhesion system consisting of tethering, rolling, firm adhesion, 
spreading, and migration of lymphocytes from the vascular space into inflamed tissue [17].  
     As secondary adhesion molecules, integrins function to stop the rolling lymphocytes and 
allow migration into intestinal tissue. Several integrin subunits are involved in lymphocyte 
migration, including α2β2, α4β1, and α4β7 [16]. These integrin subunits bind specifically to 
ligands on the endothelium, known as addressins. The α4β1 integrin binds to vascular cell 
adhesion molecule-1 (VCAM-1), whereas the α4β7 integrin binds to mucosal addressin–cell 
adhesion molecule-1 (MAdCAM-1) [1]. VCAM-1 and MAdCAM-1 are upregulated by 
inflammatory cells including TNF-α and interleukin-1 (IL-1), promoting the use of TNF inhibitors 
for IBD as well.  
     Two FDA-approved anti-integrin human monoclonal antibodies are currently approved for 
the treatment of IBD: natalizumab and vedolizumab. Natalizumab targets the α4-subunit of 
α4β1 and α4β7 integrins that are expressed on leukocytes [16]. This interaction inhibits the α4-
mediated adhesion of leukocytes to VCAM-1 and MAdCAM-1, thus preventing migration of 
leukocytes into the cell and decreasing inflammation. Natalizumab is indicated in patients with 
moderately to severely active Crohn’s disease with inadequate response to, or who are unable 
to tolerate, conventional therapies and TNF-α inhibitors [18]. Vedolizumab has similar 
pharmacologic properties to natalizumab; however, it only inhibits the α4-subunit adhesion of 
leukocytes to MAdCAM-1, not VCAM-1 [19]. Progressive multifocal leukoencephalopathy (PML) 
is a significant adverse effect of natalizumab due to inhibition of VCAM-1 activity [16]. It has 
been hypothesized that preventing α4β1 binding to VCAM-1 results in decreased immune 
surveillance within the central nervous system, in turn increasing the risk of PML [16]. Other 
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risks associated with anti-integrin monoclonal antibodies in the general population include 
infection, hepatotoxicity, and malignancy [17].   
     Morbidity and mortality in liver transplant recipients are most commonly associated with 
post-transplantation complications, including infections. Therefore, the use of these biologic 
agents in an already immunosuppressed patient population raises the concern for an increased 
risk of adverse outcomes.  
 
Literature Search 
A literature search of the PubMed database (2002-2017) was performed to identify studies 
exploring the efficacy and safety of various biologic agents for recurrent or de novo IBD in liver 
transplant recipients.  The following search terms were used: biologics, liver transplantation, 
inflammatory bowel disease, Crohn’s disease, ulcerative colitis, and immunosuppression. 
 
Results 
Demographic and Clinical Characteristics 
Fifteen case reports and case series exploring the efficacy and safety of various biologic agents 
for recurrent or de novo IBD in liver transplant recipients were identified (Table 1) [20-34]. 
From these 15 case reports, we identified 67 patients who developed de novo or recurrent IBD 
after liver transplantation, and who also received anti-TNF or anti-integrin therapy. A majority 
of patients received liver transplants for PSC (60 patients [89.6%]), with other indications 
including fulminant hepatic failure, , biliary atresia, subfulminant hepatitis, autoimmune 
hepatitis, and autoimmune sclerosing cholangitis. Of the 67 patients who developed IBD after 
liver transplantation, 38 patients (56.7%) developed recurrent IBD, whereas only 29 patients 
(43.3%) developed de novo IBD. Age at the time of transplantation ranged from 20–69 years.  
     Maintenance immunosuppression in these case reports and case series varied and included 
monotherapy or a combination of the following: tacrolimus, mycophenolate mofetil, 
prednisone, cyclosporine, basiliximab, and azathioprine. The majority of patients received 
tacrolimus (57 patients [85.1%]) either as monotherapy or as part of combination 
immunosuppression. Most patients received anti-TNF therapy for their IBD after liver 
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transplantation, with a majority receiving infliximab (39 patients [58.2%]) at some point, 
followed by adalimumab (20 patients [29.9%]). Only 22 patients (32.8%) of the liver transplant 
recipients were treated with vedolizumab for their IBD.  
 
Clinical Course Following IBD Treatment 
Of the 13 published case reports and case series reporting clinical response or remission of IBD 
activity in liver transplant recipients (59 patients), clinical response or remission of IBD was 
reported in 38 patients (64.4%). When comparing anti-TNF and anti-integrin therapies, the 
reported clinical response and remission rates in liver transplant recipients were 62.8% and 
64.7%, respectively. The definition of clinical response or remission in these published articles 
was not consistent, with some reports using the Mayo Scoring System and others using the 
Physician Global Assessment or the Harvey Bradshaw Index. Mucosal healing, defined by 
absence of ulcerations on follow-up endoscopy, varied throughout the reported cases. Of the 
five published case reports and case series (30 patients) that reported on mucosal healing, 
53.3% of patients had absence of ulcerations.  
     With respect to safety related outcomes, based on the available literature, anti-TNF and anti-
integrin therapy seems to be safe in liver transplant recipients. A majority of the cases did not 
report any significant adverse effects; however, a few cases highlighted infections and 
malignancy. A case series by Mohabbat et al of 8 patients with recurrent IBD after liver 
transplantation showed significant infectious complications including oral candidiasis, 
Clostridium difficile colitis, bacterial pneumonia, and cryptosporidiosis.[22] They also reported a 
case of Epstien-Barr virus–positive post-transplant lymphoproliferative disorder, which 
occurred 4 months after starting infliximab and 4 years after liver transplantation. Another case 
report by Sandhu et al reported a case of colorectal cancer in a patient with recurrent UC who 
received adalimumab after experiencing worsening IBD symptoms while receiving 
infliximab.[23]  Furthermore, a published abstract described the results of a meta-analysis of 
eight studies that evaluated 53 liver transplant recipients receiving anti-TNF therapy and 23 
liver transplant recipients not receiving anti-TNF therapy (control group).[35] They reported 
that the overall infection rate for TNF-exposed patients was 0.12 compared with 0.15 in the 
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control group, which represented a nonsignificant relative risk ratio of 0.80 (p=0.80). It is 
important to consider that the mean follow-up time for these patients was not consistently 
reported, and many of the reports were published within one year from transplantation or 
diagnosis of IBD. 
     There were two case reports and three case series of patients with recurrent IBD after liver 
transplantation who were treated with vedolizumab. A case report by Meszaros et al in 2015  
demonstrated clinical response to vedolizumab with no significant adverse outcomes. [28] A 
case series by Lim et al assessed the use of vedolizumab in 10 patients with PSC or autoimmune 
sclerosing cholangitis and IBD. Only 5 of the patients were liver transplant recipients.. [31] They 
reported clinical response using the Mayo endoscopy score in 40% of the patients; however, 
they did not delineate the results based on before or after liver transplantation, making it 
difficult to interpret the efficacy and safety of vedolizumab in liver transplant recipients. A more 
recent review of 10 OLT recipients by Wright et al evaluated the use of vedolizumab for the 
treatment of moderate to severe IBD. [34] The authors noted clinical improvement of IBD in 
60% of the patients, and reported that five patients experienced an infection following 
vedolizumab initiation, including Clostridium difficile colitis, cholangitis, and empyema. No 
occurrences of opportunistic fungal, viral, or mycobacterial infections were reported. In these 
high-risk patients in all 15 case reports and case series, vedolizumab was used less frequently, 
which is one of the limitations that must be acknowledged. Since vedolizumab was FDA 
approved and brought to the market more recently (2014), these patients did not have an 
appropriate follow-up period to assess for the true safety and efficacy profile of this anti-
integrin agent in liver transplant recipients. What is promising, however, is that vedolizumab is 
an available option in patients who are refractory to anti-TNF therapy and can possibly even be 
used prior to anti-TNF therapy with a theoretically lower chance to induce severe infections.   
 
Conclusion 
Patients undergoing liver transplantation secondary to PSC are at an increased risk for de novo 
or recurrent IBD, as well as other complications that may compromise graft outcomes. 
Therefore, the management of IBD in this high-risk patient population is a fine balance between 
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safety and efficacy of IBD treatment, the transplanted allograft, and infections. Data are limited 
to fully support or refute the use of biologic agents for IBD after liver transplantation; however, 
case reports and case series are available to help guide the use of these agents. Based on the 
limited available literature, the use of anti-TNF and anti-integrin therapy seems to be safe and 
effective after liver transplantation; however, the risks and benefits of these agents must be 
taken into consideration, and therapy must be individualized in a patient-specific manner. The 
safety outcomes of the biologics used in the patients in these reports were not as concerning as 
the risks labeled in their package inserts; however, a few occurrences of malignancy and mild 
infections were reported. Mechanistically speaking and from observations of anti-TNF and anti-
integrin therapies in patients both with and without transplants, vedolizumab may be a safer 
option over anti-TNF therapy due to its gut specificity and potential decreased risk for 
infectious complications.  
     It is important to note that these case reports come with significant limitations. The only 
anti-TNF agents used in the patients in these reports were infliximab and adalimumab. 
Therefore, we are unable to extrapolate the findings to certolizumab or golimumab. Pertinent 
information was lacking in these reports, including maintenance immunosuppression dosing, 
goal tacrolimus and cyclosporine levels, therapeutic monitoring of biologic agents, production 
of anti-drug antibodies, and infection history prior to transplantation. More important, there 
are inconsistencies and a lack of information from the case reports and case series regarding 
the duration of treatment for IBD prior to transplantation and the time to recurrence of IBD. 
This information would allow for a better assessment of overall duration of immunosuppression 
and risk for adverse events. Future studies should consider including these data points to allow 
for better assessment.  
     Anti-TNF and anti-integrin therapies have demonstrated clinical remission rates of 36.4–39% 
in the general IBD population, with remission ranging from 4-56 weeks after initiation, 
excluding liver transplant recipients [36-38]. Comparing remission rates in the general 
population with liver transplant recipients is difficult to assess given the heterogeneity in the 
patient population and the lack of randomized clinical trials in liver transplant recipients with 
IBD. More research is needed to confirm the true efficacy and safety of anti-TNF and anti-
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integrin therapy for IBD after liver transplantation. Ideally, a prospective randomized study 
would help identify the safe and effective use of biologics after liver transplantation; however, 
given the limited number of patients undergoing liver transplantation for PSC who have IBD, 
large retrospective studies should be performed initially. In addition to the safe and efficacious 
use of biologics for IBD after liver transplantation, several questions remain unanswered 
including optimal maintenance immunosuppression regimens and screening for colorectal 
cancer and opportunistic infections in this high-risk patient population. 
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Table 1. Summary of Case Reports and Case Series Describing the Use of Biologic Agents in Patients with IBD after Liver Transplantation 
 
Reference, no. 
of patients 
Median (range) 
age (yrs)  
Indication for 
liver 
transplantati
on 
Recurrent 
or de 
novo IBD 
Immunosuppressio
n after liver 
transplantation 
IBD treatment 
before liver 
transplantation 
IBD 
treatment 
after liver 
transplantati
on 
 
Clinical 
outcome: 
response 
rate (%) 
Endoscopic 
outcome: 
mucosal 
healing (%) 
Adverse events 
Lal et al.
20
  
(2007) 
(n=1) 
 
 
29 PSC (n=1) Recurrent 
(n=1) 
Tac (n=1) 5-ASA (oral and 
enema), steroids, 
AZA (n=1) 
IFX (n=1) 
 
 
100 100 None 
El-Nachef et 
al.
21
  
(2010) 
(n=2) 
 
53.5 (43-64) Fulminant 
hepatic 
failure (n=1) 
 
PSC (n=1) 
Recurrent 
(n=1) 
 
de novo 
(n=1) 
 
Tac (n=1) 
Tac, MMF, pred 
(n=1) 
 
Steroids and 5-
ASA (n=1) 
5-ASA and 
budesonide (n=1) 
 
IFX (n=1) 
 
ADA (n=1) 
 
100 NR None 
Mohabbat et 
al.
22
  
(2012) 
(n=8) 
42 (22-69) PSC (n=8) Recurrent 
(n=8) 
Tac, pred (n=2) 
Tac, pred, AZA (n=2) 
Tac (n=1) 
CsA, AZA (n=2) 
CsA, pred (n=1) 
5-ASA (n=5) 
Immunomodulat
ors: AZA, 6-MP 
and/or MTX (n=4) 
Steroids (n=6) 
IFX (n=4) 
 
ADA  IFX 
(n=2) 
 
ADA (n=2) 
87.5 42.9 (n=7) Oral candidiasis, 
Clostridium difficile 
colitis, bacterial 
pneumonia, 
cryptosporidiosis, 
Epstein-Barr virus–
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positive post-transplant 
lymphoproliferative 
disorder 
Sandhu et al.
23
 
(2012) 
(n=6) 
 
51.5 (28-65) AIH (n=1) 
 
PSC (n=4) 
 
Biliary atresia 
(n=1) 
 
Recurrent 
(n=3) 
 
de novo 
(n=3) 
Tac, MMF, pred 
(n=3) 
Tac, MMF (n=1) 
Tac (n=1) 
CsA, AZA (n=1) 
 
NR IFX (n=4) 
 
IFX  ADA 
(n=2) 
 
67 NR Systemic lupus 
erythematous, 
colorectal cancer 
Alvaro et al.
24
 
(2013) 
(n=1) 
 
42 Subfulminant 
hepatitis 
(n=1) 
de novo 
(n=1) 
Tac (n=1) NR ADA (n=1) 100 NR None 
Indriolo et al.
25
 
(2013) 
(n=4) 
39 (22-54) PSC (n=4) Recurrent 
(n=4) 
Tac, pred, AZA (n=1) 
Tac (n=1) 
Tac, sirolimus (n=1) 
CsA (n=1) 
 
NR IFX (n=4) 75 33 (n=3) Molluscum contagiosum 
Schnitzler et 
al.
26
 (2015) 
(n=3) 
43 (32-65) PSC (n=3) Recurrent 
(n=3) 
Tac (n=2) 
Tac, steroids (n=1) 
AZA (n=1) 
5-ASA (n=1) 
5-ASA, steroids 
IFX (n=2) 
 
ADA (n=1) 
NR NR None Au
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 (n=1)  
Naito et al.
27
  
(2015) 
(n=1) 
 
23 Biliary atresia 
(n=1) 
de novo 
(n=1) 
CsA (n=1) NR IFX (n=1) 100 NR None 
Meszaros M et 
al.
28
  
(2015) 
(n=1) 
 
40 PSC (n=1) Recurrent 
(n=1) 
NA Pred, AZA IFX  VED 
(n=1) 
100 NR None 
Karolina et al.
29
  
(2014) 
(n=1) 
29 PSC (n=1) Recurrent 
(n=1) 
Tac, MMF, pred 
(n=1) 
5-ASA, AZA  (n=1) IFX (n=1) 100 NR None 
Combes et al.
30
 
(2017)
 
(n=18) 
37.2 (24.0-51.9) PSC (n=18) de novo 
(n=18) 
Tac (n=17) 
CsA (n=1) 
 
NR IFX (n=7) 
ADA (n=7) 
IFX  ADA 
(n=4) 
 
38.9 64.3 (n=14) Infection (undefined), 
colon cancer 
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Lim et al.
31 
(2016) 
(n=5) 
42.4 (21-57) PSC (n=4) 
 
AISC (n=1) 
Recurrent 
(n=5) 
Tac (n=2) 
Tac, MMF, pred 
(n=1) 
Tac, AZA, pred (n=1) 
Pred (n=1) 
 
NR VED (n=5) NR NR Abnormalities in liver 
biochemistry 
Hartery et al.
32
 
(2017) 
(n=5) 
40.7 (32.5-68.7) PSC (n=5) Recurrent 
(n=3) 
 
de novo 
(n=2) 
 
Tac (n=2) 
Tac, MMF, pred 
(n=1) 
Tac, MMF (n=1) 
Tac, pred (n=1) 
5-ASA (n=1) 
AZA (n=1) 
IFXVED 
(n=5) 
60 40 None 
Daffra et al.
33
 
(2017) 
(n=1) 
20 PSC (n=1) Recurrent 
(n=1) 
NA 5-ASA, pred (n=1) VED (n=1) 100 NR NR 
Wright et al. 
(2017)
34
 
(n=10) 
36 (28.5-50) PSC (n=9) 
Hepatitis C 
(n=1) 
Recurrent 
(n=7) 
  
de novo 
(n=3) 
Tac, MMF, pred 
(n=9) 
Basiliximab, Tac, 
MMF, pred (n=1) 
5-ASA (n=9) 
AZA (n=4) 
IFX (n=3) 
ADA (n=3) 
VED (n=3) 
VED (n=10) 60 NR Cholangitis (n=4) 
Clostridium difficile 
colitis (n=4) 
Empyema (n=2) 
Pneumonia (n=1) 
IBD = inflammatory bowel disease; PSC = primary sclerosing cholangitis; NR = not reported AIH = autoimmune hepatitis; AISC = autoimmune sclerosing cholangitis; Tac = tacrolimus; 5-ASA = 
aminosalicylate; AZA = azathioprine; MMF = mycophenolate mofetil; pred= prednisone; IFX = infliximab; ADA = adalimumab; CsA = cyclosporine; 6-MP= 6-mercaptopurine; MTX = methotrexate; VED 
= vedolizumab. 
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